Cambridge Vision Technology develops technology for the timely and accurate detection of Alzheimer's Disease. The company focuses on creating accessible diagnostic solutions for this neurological condition. Their core offering aims to improve early intervention capabilities for Alzheimer's patients.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early detection and monitoring of Alzheimer's Disease and other neurodegenerative conditions are challenging due to the lack of accessible and accurate diagnostic tools. Current methods often rely on subjective assessments and may not detect subtle changes indicative of early-stage disease. This can lead to delayed intervention and poorer patient outcomes.
Solution
Cambridge Vision Technology develops integrated medical devices that provide timely and accurate diagnostic tests for the early detection and monitoring of Alzheimer's Disease and other neurodegenerative conditions. Their technology utilizes specific biomarkers to identify subtle indicators of disease progression, enabling earlier intervention and potentially improving patient outcomes. By providing clinicians with objective and quantifiable data, Cambridge Vision Technology aims to enhance the accuracy and efficiency of neurodegenerative disease diagnosis and management.
Target Audience
The primary target audience includes neurologists, geriatricians, and other healthcare professionals involved in the diagnosis and management of neurodegenerative diseases.
Features
- Integrated medical devices for in-clinic use
- Biomarker-based diagnostic tests
- Objective and quantifiable data output
- Early detection capabilities for Alzheimer's Disease and other neurodegenerative conditions